Sökning: WFRF:(Svensson Ulrika) > The multistate tube...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04608naa a2200469 4500 | |
001 | oai:DiVA.org:uu-318691 | |
003 | SwePub | |
008 | 170328s2017 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3186912 URI |
024 | 7 | a https://doi.org/10.1007/s10928-017-9508-22 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Chen, Chunliu Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)chuch828 |
245 | 1 0 | a The multistate tuberculosis pharmacometric model :b a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model |
264 | c 2017-02-15 | |
264 | 1 | b Springer Science and Business Media LLC,c 2017 |
338 | a electronic2 rdacarrier | |
520 | a The Multistate Tuberculosis Pharmacometric (MTP) model, a pharmacokinetic-pharmacodynamic disease model, has been used to describe the effects of rifampicin on Mycobacterium tuberculosis (M. tuberculosis) in vitro. The aim of this work was to investigate if the MTP model could be used to describe the rifampicin treatment response in an acute tuberculosis mouse model. Sixty C57BL/6 mice were intratracheally infected with M. tuberculosis H37Rv strain on Day 0. Fifteen mice received no treatment and were sacrificed on Days 1, 9 and 18 (5 each day). Twenty-five mice received oral rifampicin (1, 3, 9, 26 or 98 mg·kg-1·day-1; Days 1–8; 5 each dose level) and were sacrificed on Day 9. Twenty mice received oral rifampicin (30 mg·kg-1·day-1; up to 8 days) and were sacrificed on Days 2, 3, 4 and 9 (5 each day). The MTP model was linked to a rifampicin population pharmacokinetic model to describe the change in colony forming units (CFU) in the lungs over time. The transfer rates between the different bacterial states were fixed to estimates from in vitro data. The MTP model described well the change in CFU over time after different exposure levels of rifampicin in an acute tuberculosis mouse model. Rifampicin significantly inhibited the growth of fast-multiplying bacteria and stimulated the death of fast- and slow-multiplying bacteria. The data did not support an effect of rifampicin on non-multiplying bacteria possibly due to the short duration of the study. The pharmacometric modelling framework using the MTP model can be used to perform investigations and predictions of the efficacy of anti-tubercular drugs against different bacterial states. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng |
653 | a Mouse | |
653 | a Rifampicin | |
653 | a Tuberculosis | |
653 | a Pharmacokinetics | |
653 | a Pharmacodynamics | |
700 | 1 | a Ortega, Fatimau Diseases of Developing World Medicines Development Campus, GlaxoSmithKline, Madrid, Spain4 aut |
700 | 1 | a Rullas, Joaquinu Diseases of Developing World Medicines Development Campus, GlaxoSmithKline, Madrid, Spain4 aut |
700 | 1 | a Alameda, Laurau Diseases of Developing World Medicines Development Campus, GlaxoSmithKline, Madrid, Spain4 aut |
700 | 1 | a Angulo-Barturen, Iñigou Diseases of Developing World Medicines Development Campus, GlaxoSmithKline, Madrid, Spain.; Art Discovery TAD, Biscay Sci & Technol Pk,BIC Bizkaia Bldg,612, Bizkaia 48160, Basque Country, Spain4 aut |
700 | 1 | a Ferrer, Santiagou Diseases of Developing World Medicines Development Campus, GlaxoSmithKline, Madrid, Spain4 aut |
700 | 1 | a Svensson, Ulrika S Hu Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)usv12211 |
710 | 2 | a Uppsala universitetb Institutionen för farmaceutisk biovetenskap4 org |
773 | 0 | t Journal of Pharmacokinetics and Pharmacodynamicsd : Springer Science and Business Media LLCg 44:2, s. 133-141q 44:2<133-141x 1567-567Xx 1573-8744 |
856 | 4 | u https://doi.org/10.1007/s10928-017-9508-2y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1085399/FULLTEXT01.pdfx primaryx Raw objecty fulltext:postprint |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1085399/FULLTEXT02.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://link.springer.com/content/pdf/10.1007%2Fs10928-017-9508-2.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-318691 |
856 | 4 8 | u https://doi.org/10.1007/s10928-017-9508-2 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy